Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses (Tables)

v3.20.1
Accrued Expenses (Tables)
 3 Months Ended
Mar. 31, 2020
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses

Accrued expenses consisted of the following:

 

   

March 31,

2020

     December 31,
2019		  
Accrued clinical operations and trials costs   $ 16,145,019     $ 14,242,669  
Accrued product development costs     3,232,262       3,573,231  
Accrued compensation     2,849,954       3,673,111  
Accrued other     1,289,119       958,928  
Total   $ 23,516,354     $ 22,447,939